Inari Medical, Inc. (NARI) Stock

About Inari Medical, Inc.

Inari Medical, Inc. is a medical technology firm focused on creating, producing, promoting, and distributing devices for the minimally invasive management of venous conditions within the United States. Their product portfolio includes ClotTriever, a mechanical thrombectomy solution designed to extract significant clots from major blood vessels, specifically targeting deep vein thrombosis. Another key offering is FlowTriever, a substantial catheter-based aspiration and mechanical thrombectomy system, which addresses pulmonary embolism. The company also provides FlowSaver; FlowStasis, a large-bore suture retention device to manage venous access points; and FlowTriever 2, an enhanced version with a new disk design for efficiently capturing wall-adherent clots and reducing procedure time. Founded in 2011, the company was initially known as Inceptus Newco1 Inc. before rebranding as Inari Medical, Inc. in September 2013. Its corporate headquarters are located in Irvine, California.

Inari Medical, Inc. is headquartered in US.

Inari Medical, Inc. (NARI) stock trades at $79.97 with a market capitalization of $4.68B. The stock is valued at a price-to-earnings (P/E) ratio of -2776.74, price-to-book of 9.77, price-to-sales of 9.49. Over the past 52 weeks the stock has ranged between $36.73 and $79.99, and currently trades at its 52-week high.

On profitability, Inari Medical, Inc. generates a return on equity (ROE) of -0.37%, return on capital employed of -2.35%, an operating margin of -2.84%, a net profit margin of -0.33%.

Official website: www.inarimedical.com